Last update 21 Nov 2024

SPEAR T cell therapies (Adaptimmune/Alpine Immune)

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

TCR therapy

Synonyms

Next Generation TCR T-cell Therapies(Alpine Immune), SIPs and TIPs, Secreted and Transmembrane Immunomodulatory Proteins

Target-

Mechanism

Immunologic cytotoxicity, T lymphocyte replacements

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

Adaptimmune Ltd.

Alpine Immune Sciences, Inc.

Active Organization

Alpine Immune Sciences, Inc.

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

100 Clinical Results associated with SPEAR T cell therapies (Adaptimmune/Alpine Immune)

100 Translational Medicine associated with SPEAR T cell therapies (Adaptimmune/Alpine Immune)

100 Patents (Medical) associated with SPEAR T cell therapies (Adaptimmune/Alpine Immune)

Literatures (Medical) associated with SPEAR T cell therapies (Adaptimmune/Alpine Immune)

01 Nov 2023·Pest management science

Structural insight into Bacillus thuringiensis Sip1Ab reveals its similarity to ETX_MTX2 family beta-pore-forming toxin.

Article

Author: Shi, Yiting ; Wang, Dongdong ; Liu, Xiaoyu ; Chen, Zhe ; Jiang, Kun ; Jiao, Xuyao ; Gao, Xiang

BACKGROUNDMicrobially derived, protein-based biopesticides are an important approach for sustainable pest management. The secreted insecticidal proteins (Sips) produced by the bacterium Bacillus thuringiensis exhibit potent insecticidal activity against coleopteran pests and are, therefore, attractive as candidate biopesticides. However, the modes-of-action of Sips are unclear as comprehensive structural information for these proteins is lacking.RESULTSUsing X-ray crystallography, we elucidated the structure of monomeric Sip1Ab at 2.28 Å resolution. Structural analyses revealed that Sip1Ab has the three domains and conserved fold characteristic of other aerolysin-like beta-pore-forming toxins (β-PFTs). Based on the sequence and structural similarities between Sip1Ab and other ETX_MTX2 subfamily toxins, we suggested the mechanism of these proteins and proposed that it is common to them all.CONCLUSIONThe atomic-level structural data for Sip1Ab generated by the present study could facilitate future structural and mechanistic research on Sips as well as their application in sustainable insect pest management. © 2023 Society of Chemical Industry.

01 Jan 2023·Therapeutic Advances in Medical Oncology

Emerging targets in gastroesophageal adenocarcinoma: what the future looks like

Review

Author: Petrillo, Angelica ; van Laarhoven, Hanneke W. M. ; Smyth, Elizabeth C.

Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases. Recently, the introduction of immunotherapy demonstrated improved survival outcomes in localized and metastatic diseases. Beyond immunotherapy, several attempts were made to improve patient survival by understanding the molecular mechanisms of GEA and several molecular classifications were published. In this narrative review, we will discuss emerging targets in GEA, including fibroblast growth factor receptor and Claudin 18.2, as well as the accompanying drugs. In addition, novel agents directed against well-known targets, such as HER2 and angiogenesis, will be discussed, as well as cellular therapies like CAR-T and SPEAR-T cells.

01 Dec 2018·International Journal of Biological MacromoleculesQ1 · CHEMISTRY

Sarcodon imbricatus polysaccharides protect against cyclophosphamide-induced immunosuppression via regulating Nrf2-mediated oxidative stress

Q1 · CHEMISTRY

Article

Author: Wu, Honghong ; Song, Jia ; Wang, Xue ; Teng, Lesheng ; Jia, Wei ; Yang, Xige ; Wang, Di ; Wang, Zhuqian

Sarcodon imbricatus, a rare medicinal and edible fungus, has various pharmacological bioactivities. The present study systematically investigated the protective effects of S. imbricatus polysaccharides (SIPS) against cyclophosphamide (CTX)-induced immunosuppression in Balb/c mice model. Compared with the CTX-induced immunosuppressive mice, the spleen and thymus indexes in the mice with 28-day SIPS orally administration were significantly increased, bodyweight loss was alleviated, and the natural killer (NK) cytotoxicity and the proliferative activities of lymphocytes were elevated. SIPS regulated the production of immunoglobulins including IgA, IgG and IgM in the serum and spleen. Notably, SIPS promoted the secretion of interleukin-2 (IL-2), IL-6, IL-10, IL-12 and interferon-γ (IFN-γ) of serum and spleen in CTX-induced immunosuppressive mice. Additionally, SIPS inhibited reactive oxygen species (ROS) levels and increased total antioxidant capacity, including superoxide dismutase (SOD), glutathione peroxidase (GSH-Px) and catalase (CAT) activities of spleen and thymus, as well as enhanced acid phosphatase (ACP) and lysozyme (LZM) levels of thymus in CTX-induced immunosuppressive mice. Histopathological analysis of spleen revealed the protective effect of SIPS against CTX-induced immunosuppression. More importantly, SIPS promoted the expression of nuclear factor-erythroid 2-related factor 2 (Nrf2) and its downstream target genes encoding antioxidant enzymes: SOD1, SOD2, haem oxygenase-1 (HO-1), CAT and quinone oxidoreductase 1 (NQO1). Altogether, SIPS reversed CTX-induced immunosuppression effectively and predominantly through Nrf2-mediated oxidative stress, which provided the useful evidence that SIPS can be served as a novel natural immunomodulator in health foods or medicine.

100 Deals associated with SPEAR T cell therapies (Adaptimmune/Alpine Immune)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Preclinical	US	Alpine Immune Sciences, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

SPEAR T cell therapies (Adaptimmune/Alpine Immune)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation